INTRODUCTION
Blast crisis is the terminal phase of chronic myelogenous leukemia (CML), a clonal myeloproliferative disorder of the hematopoietic stem cell which typically evolves in three distinct clinical stages: chronic and accelerated phase and blast crisis 1, 2 . The chronic phase lasts several years and is characterized by accumulation of myeloid precursors and mature cells in bone marrow, peripheral blood and extramedullary sites 1, 2 . The accelerated phase lasts 4 to 6 months and is characterized by an increase in disease burden and in the frequency of progenitor/ precursor cells rather than terminally differentiated cells. The blast crisis lasts only a few months and is characterized by the rapid expansion of a population of myeloid or lymphoid differentiation-arrested blast cells 3 . CML is consistently associated with an acquired genetic abnormality, the Philadelphia chromosome (Ph 1 ), a shortened chromosome 22 resulting from a reciprocal translocation of the long arms of chromosomes 9 and 22 4, 5 . This translocation generates the BCR/ABL fusion gene which is translated in the p210 BCR/ABL oncoprotein 6, 7 of almost all CML patients.
Two other BCR/ABL proteins, p190 and p230, generated by variant fusion genes, are only occasionally detected in classic CML 8 . Expression of p210 BCR/ABL is necessary and sufficient for malignant transformation, as demonstrated in in vitro assays and leukemogenesis in mice [9] [10] [11] [12] [13] . Transition to blast crisis is the unavoidable outcome of CML except in a cohort of patients receiving allogeneic bone marrow transplantation early in the chronic phase 14 . The development of the BCR/ABL tyrosine kinase inhibitor Gleevec (imatinib mesylate; formerly STI571) as the treatment of choice for chronic phase CML and its remarkable therapeutic effects suggests that blast crisis transition will be postponed for several years in the majority of CML patients 15, 16 . However, the persistence of BCR/ABL transcripts in a cohort of patients with complete cytogenetic response raises the possibility that treatment with Gleevec alone might not prevent disease progression 17 .
The mechanisms responsible for transition of CML chronic phase into blast crisis remain poorly understood, although a reasonable assumption is that the unrestrained activity of BCR/ABL in hematopoietic stem/progenitor cells is the primary determinant of disease progression. No causal relationship has been demonstrated yet between BCR/ABL expression, which specifically increases during disease progression 18, 19 in hematopoietic stem cells and only.
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However, a plausible model of disease progression predicts that increased BCR/ABL expression promotes the secondary molecular and chromosomal changes essential for the expansion of cell clones with increasingly malignant characteristics, and remains crucial for the malignant phenotype even in advanced stages of the disease (Fig. 1 ). Increased expression of BCR/ABL, frequently observed in patients with blast crisis CML, might promote secondary molecular and genetic abnormalities which contribute to the expansion of a cell population characterized by enhanced proliferation, increased resistance to apoptosis and differentiation arrest.
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While there is no indication yet that Gleevec-resistant patients have a clinically distinct disease, it is possible that they will present distinct genetic abnormalities, the appearance of which could be influenced by the duration of BCR/ABL-dependent signals. Thus, the biology of CML blast crisis in the pre-Gleevec and in the Gleevec eras may be different. With this in mind, we will illustrate the molecular mechanisms underlying transition to CML blast crisis according to a model of disease progression in which: i) BCR/ABL activity is necessary for the accumulation of secondary genetic abnormalities and/or changes in gene expression; and ii) such secondary events directly or indirectly promote differentiation arrest, the distinctive feature of CML blast crisis.
Effects of BCR/ABL on proliferation and survival of myeloid progenitor cells
In hematopoietic CML cells carrying the Ph 1 chromosome, the BCR/ABL fusion gene encodes p210
, an oncoprotein which, unlike the normal p145 c-Abl, has constitutive tyrosine kinase activity 21 and is predominantly localized in the cytoplasm 22 Ectopic expression of BCR/ABL in growth factor-dependent cell lines leads to the activation of numerous signal transduction pathways responsible for growth factor independence and reduced susceptibility to apoptosis of these cells (Fig. 2) . 
RAS pathway
The RAS pathway becomes constitutively activated by alternative mechanisms involving the interaction of BCR/ABL with the GRB-2/Gab2 complex, via the GRB-2 binding site in the BCR portion of BCR/ABL, and the recruitment/phosphorylation of the SHC adaptor 26,27 .
The interaction of BCR/ABL with GRB-2/Gab2 and the phosphorylation of SHC lead to enhanced activity of the GDP/GTP exchange factor SOS, which promotes the accumulation of the active GTP-bound form of RAS (Fig. 2) . The importance of RAS-dependent signaling for 
PI-3K/Akt pathway
The phosphatidylinositol-3 kinase (PI-3K) is another important pathway activated by ectopic expression of oncogenic Abl proteins 31, 32 . BCR/ABL interacts indirectly with the p85 regulatory subunit of PI-3K 33 via various docking proteins including GRB-2/Gab2 and c-cbl 27, 34 ( Fig. 2) . PI-3K activation via the GRB-2/Gab2 interaction appears pathologically relevant as Gab2-deficient marrow cells are resistant to BCR/ABL transformation 27 .
Activation of the PI-3K pathway triggers an Akt-dependent cascade which has a critical role in BCR/ABL transformation 35 by regulating the subcellular localization and/or activity of several targets such as BAD, MDM2, I B-kinase-, and members of the Forkhead family of transcription factors 36 ( Fig. 2) . Phosphorylation of BAD suppresses its pro-apoptotic activity because, when phosphorylated, BAD is sequestered in the cytoplasm in a complex with 14-3-3 37 . In BCR/ABL-expressing cells, BAD is cytoplasmic and heavily phosphorylated 38 .
Ectopic expression of a mutant form of BAD which cannot be phosphorylated by Akt induces massive apoptosis 38 , suggesting that inactivation of BAD pro-apoptotic effects is important for survival of BCR/ABL-expressing cells. Phosphorylation of MDM2 enhances its nucleuscytoplasm export, potentially inducing a more efficient degradation of p53 39, 40 . Phosphorylation of the I B-kinase-enhances its activity toward I B, its substrate 41 . Upon phosphorylation, I B is subjected to ubiquitination and proteasome-dependent degradation, allowing the translocation of NF-B into the nucleus where it functions as a transcription factor 42 . Thus, the net effect of 
STAT5 pathway
Another anti-apoptotic pathway activated by BCR/ ABL is that dependent on STAT5 65 . In that study, proliferative potential and growth factor response of CML progenitors were also tested, but these progenitors were apparently functionally undistinguishable from their normal counterparts 65 .
Cell cycle regulation by BCR/ABL
The precise effects of BCR/ABL on proliferation of CML progenitors remain unclear:
reports of higher than normal frequency of actively cycling progenitors 66, 67 coexist with studies that failed to find increased cell proliferation rates in CML 68, 69 . Highly purified subsets of CML 72 .
At the molecular level, exit from quiescence induced by BCR/ABL in primitive progenitor cells might depend on its effect on cyclin(s) and Cdk inhibitor(s). For example, cyclin D2 levels are increased in BCR/ABL-expressing lymphoblasts 73 and are required for stimulation of proliferation induced by BCR/ABL in these cells 74 , and downregulation or cytoplasmic relocation of p27 has been demonstrated in mouse and human lymphoid and myeloid BCR/ABL-expressing cells 74, 75 . In light of the role of the p21 and p27 Cdk inhibitor in maintaining quiescence and regulating the expansion of hematopoietic stem cells and early progenitors 76, 77 , the ability of BCR/ABL to modulate levels of cyclin and Cdk inhibitors may be the critical mechanism promoting cell cycle entry of primitive hematopoietic cells. Autocrine production of IL-3 by primitive Ph 1 CML progenitors has been also proposed as a mechanism leading to the initial expansion of these cells 78 and would, in turn, increase cyclin D2 and downregulate p27 levels, possibly allowing CML primitive progenitors to leave quiescence and start cycling.
A possible explanation for the different effects induced by endogenous BCR/ABL in the CD34 + and CD34 -subset may rest in its levels of expression: low levels of BCR/ABL expression typically found in the majority of CML cells may be sufficient for anti-apoptotic, but not for proliferative signals, whereas higher levels of BCR/ABL expression in the more primitive subsets of CD34 + cells may be sufficient for both anti-apoptotic and proliferative signals.
In summary, the molecular signature of BCR/ABL-expressing cells is consistent with the phenotype of these cells and implicates reduced apoptosis susceptibility and enhanced proliferative potential of specific cell subsets in disease progression.
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Effect of BCR/ABL on DNA repair
The transition of CML from chronic phase to blast crisis is characterized by the accumulation of molecular and chromosomal abnormalities 79 , but the molecular mechanisms underlying this genetic instability are poorly understood. In the past 2-3 years, few studies have directly addressed the relationship between BCR/ABL expression and levels/activity of proteins involved in DNA repair, particularly the repair of DNA double-strand breaks.
In the first study investigating such a relationship, Deutsch et al. 80 Repair of DSBs by the DNA-PK-dependent pathway (non-homologous end-joining recombination) is very important because this is the preferred pathway utilized by human cells 87 .
In mice, non-homologous end-joining (NHEJ) deficiency accelerates lymphoma formation and promotes the development of soft tissue sarcomas that possess clonal amplifications, deletions and translocations 88, 89 . In BCR/ABL-expressing cells (including primary CML cells), levels of DNA-PK CS were markedly downregulated 80 and were reversed by proteasome inhibitors, suggesting the activation of a BCR/ABL-dependent pathway leading to enhanced proteasome-dependent protein degradation 80 . Downregulation of DNA-PK CS levels was associated with a higher frequency of chromosomal abnormalities after exposure of BCR/ABL-expressing cells to ionizing radiation (IR) and increased radiosensitivity 80 . Such an increase was, however, modest probably due to enhanced survival of BCR/ABL-expressing cells caused by the activation of multiple anti-apoptotic pathways.
The same group also reported an association of BCR/ABL expression in primary CML samples and in established cell lines with downregulation of BRCA-1 90 , a protein involved in the surveillance of genome integrity 91, 92 . Downregulation of BRCA-1 was more evident in cell lines only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From in which levels of BCR/ABL were more abundant and was correlated with an increased rate of sister chromatid exchange and chromosome aberration after DNA damage. The limitation of these studies is that they have not been yet confirmed in a large cohort of primary samples obtained from CML patients and that a causal link between decreased repair of DSBs and disease progression has not been demonstrated. The availability of embryonic and somatic cells with targeted disruption of several genes required for the NHEJ repair of DSBs makes possible the development of mouse models in which to investigate whether defects in this pathway of DNA repair are relevant for BCR/ABL leukemogenesis and disease progression.
Another group identified BCR/ABL-dependent pathways leading to enhanced expression/ activity of RAD51 93 , a protein that participates in homologous recombination repair (HRR) 94 .
Expression of BCR/ABL increased the efficiency of HRR in a RAD51-dependent manner, as well as resistance to apoptosis induced by drugs like mitomycin C and cisplatin which promote DSBs 93 . In light of enhanced high-fidelity HRR promoted by RAD51 94 , it seems counterintuitive that the increased expression/activity of RAD51 (and other paralogues) in BCR/ABL-expressing cells might be associated with genomic instability. Yet, such an increase may result in undesired effects such as a higher frequency of intra-or inter-chromosomal deletions and chromosomal translocations dependent on recombination between highly homologous members of the Alu sequence repeat family 95, 96 . HRR-dependent mechanisms have been also associated with loss of heterozygosity by gene conversion mechanisms, and with promotion of small mutations or insertions 96 .
Together, the apparently opposite effects of BCR/ABL on RAD51, DNA-PK CS , and BRCA-1 may not be mutually exclusive and may all be involved in promoting genomic instability associated with defective repair of DSBs (Fig. 3) . Dysregulation of the DNA repair mechanisms discussed above and the acquisition of mutations in genes critically important for the regulation of proliferation is expected to activate control checkpoints (i.e. p53 expression), which may lead to the elimination of cells with damaged DNA. However, the ability of BCR/ABL to regulate multiple anti-apoptotic pathways, perhaps in a dose-dependent manner and in specific subsets of progenitor cells, is likely to allow survival of cell populations carrying mutations which promote their proliferation and maintenance (Fig. 3) .
only. 
Mechanisms of disease progression: mouse models
Although the BCR/ABL oncoprotein plays a central role in the pathogenesis of chronic phase CML and its continued expression/activity remains important for maintenance of leukemia in mice 97 and for proliferation and/or survival of blast crisis cells in humans 98 , the molecular events responsible for the evolution to blast crisis remain unclear. Accelerated phase and blast crisis CML are characterized by the appearance of various molecular and chromosomal alterations 3 . Accordingly, disease models have been generated to mimic simultaneously the effect of BCR/ABL and of a specific secondary genetic abnormality. This approach has allowed investigators to establish a correlation between disease phenotype and the presence of certain only.
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Transduced cells express BCR/ABL at high levels and induce a rapidly fatal myeloproliferative disorder which precludes assessment of mechanisms of disease progression.
The leukemogenic potential of the BCR/ABL gene was first tested in transgenic mice using the p190 and p210 BCR/ABL cDNA driven by the metallothionein (MT) 97 .
Using an inducible model in which p210 bcr/abl expression was under the control of human CD34 regulatory elements, the same group showed that transgenic mice all died within 2 to 14 months and the predominant features were chronic thrombocytosis, a marked increase of megakaryocytes in bone marrow and spleen, and the development of splenomegaly accompanied by lymphadenopathy in some mice 104 (Table 1) .
Altogether, it is clear that the available mouse models of BCR/ABL-induced diseases do not closely mimic CML in humans and that a better understanding of mechanisms of disease progression will require the generation of other transgenic lines (besides the CD34-p210 bcr/abl model) in which BCR/ABL-expression is under the control of promoters active only in primitive hematopoietic progenitors.
Additional mouse models of BCR/ABL leukemogenesis could be generated based on pioneering work of Rabbitts and collaborators, who used homologous recombination to target the MLL-AF9 human gene of the t(9;11) translocation to the MLL gene locus 105 : such "knockin" strategy led to the development of acute myeloid leukemia in chimeric mice 105 .
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The "knockin" strategy was used to fuse p190 bcr/abl coding sequences into the endogenous bcr gene 106 . By 4 months of age, 95% of chimeric mice expressing one p190 bcr/abl allele developed pre B-ALL 106 (Table 1) . Since no information is available on the use of this "knockin" strategy to target p210 bcr/abl at the bcr locus, it is likely that bcr-regulated expression of p210 bcr/abl is toxic for embryonal cells 107 . In this regard, the "knockin" approach to generate alleles mimicking the translocation fusion genes was combined with Cre-mediated recombination to prevent the toxic effects for embryonal cells of the AML1-ETO fusion protein of the t(8;21) translocation 108 . Activation of AML1-ETO expression resulted in the expansion of myeloid progenitors, but neither blocked differentiation nor promoted leukemia development 108 .
Treatment of these mice with a single mutagenic dose of the DNA alkylating agent N-ethyl-Nnitroso-urea induced hematopoietic neoplasms 2-10 months after treatment 108 .
These genetic approaches have been elegantly utilized to obtain a de novo translocation in mice mimicking the t(11;19) that generates the MLL-ENL fusion gene 109 . As in humans, the chromosomal translocation between the mouse MLL and ENL genes resulted in the rapid development of leukemia 109 .
The establishment of disease models of BCR/ABL-induced leukemia with a long myeloproliferative phase would be necessary for assessing mechanisms of disease progression. only.
Mechanisms of disease progression: genetic events
Cytogenetic and molecular changes occur in the vast majority of CML patients during evolution to blast crisis (Fig. 4) . Thus, a recurring question has been whether p210 bcr/abl induces genomic instability directly or increasingly frequent genetic abnormalities during disease progression are acquired secondarily. Also, neither situation excludes that genetic instability of CML blast crisis depends both on increased propensity of BCR/ABL-expressing cells to undergo genetic changes and the probability that one of the mutations induced by BCR/ABL functions as an "amplifier" of a genetically unstable phenotype. • t(7;11)(p15;p15) (<1%) While it is believed that the persistent expression of BCR/ABL, per se, leads to genomic instability, there is also a cohort of CML patients (10-15%) presenting with deletions of the Microsatellite instability, a feature associated with tumor progression, does not seem to be involved in CML disease progression 115, 116 .
GENETIC
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Regardless of whether BCR/ABL has a direct or an indirect role in promoting genomic
instability, 60 to 80% of CML patients develop additional non-random chromosomal abnormalities involving chromosomes 8,17,19 and 22 with duplication of the Ph chromosome or trisomy 8 being the most frequent 117 (Fig. 4) .
At the molecular level, mutation of the tumor suppressor gene p53 is detected in approximately 25-30% of CML-myeloid blast crisis 118, 119 while approximately 50% of the patients with lymphoid blast crisis present a homozygous deletion at the INK4A/ARF gene locus located on chromosome 9 120 (Fig. 4) . The most common chromosomal changes are trisomy of chromosome 8 (34%), trisomy of chromosome 19 (13%), double Ph chromosome (38%), isochromosome i(17q) (20%); these abnormalities can be also found in various combinations.
Based on the frequency of the combinations in all metaphases and subclones, it has been suggested that i(17q) and trisomy of chromosome 8 are early changes, while trisomy 19 might occur late during disease progression 121 . Some combinations, [trisomy 8, double Ph chromosome and i(17q)], are more frequent than others; but, neither the presumed order of appearance nor the combination itself seems to have a clear impact on the prognosis of CML-BC 117 . Moreover, the frequency of some secondary changes seems to depend on the therapeutic regimen 117 .
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From For example, chromosome 8 trisomy is more frequent in CML patients treated with busulfan (44%) than in those receiving hydroxyurea (12%). The frequency of the common CML secondary changes in interferon-(IFN)-treated patients and especially after bone marrow transplantation appears to be lower than in the busulfan-treated group 117 , suggesting that the treatment with DNA-damaging agents (i.e. busulfan) accentuates the genetic instability caused by the unrestrained tyrosine kinase activity of BCR/ABL. It will be interesting to see whether evolution into CML-BC of Gleevec-treated CML patients is also associated with a subset of the chromosomal abnormalities found in the "historical" group of CML patients predominantly treated with busulfan and/or hydroxyurea.
Role of chromosomal abnormalities in CML disease progression
Whether and how the most common chromosomal abnormalities of CML-BC are pathogenetically linked to disease progression remains unclear and difficult to prove.
Chromosome 8 trisomy
Because the MYC gene is located at 8q24, it may be expected that chromosome 8 trisomy 
Isochromosome i(17q)
A correlation between this genetic abnormality and a molecular mechanism of disease progression has not been established yet. The i(17q) abnormality leads to loss of 17p and has only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From been thought to be associated with mutation of the remaining p53 allele. However, p53 mutations were not found in CML cases with the i(17q) 127, 128 , raising the possibility that the relevant pathogenetic mechanism in CML-BC patients with the i(17q) abnormality is loss of function of yet unidentified genes. It is also possible that genetic inactivation of a p53 allele in combination with BCR/ABL-dependent effects (see below) on the expression/activity of the remaining one remains the pathogenetically relevant mechanism in CML-BC with this chromosomal abnormality.
Double Ph chromosome
The role of the double Ph chromosome in disease progression is also unclear. Perhaps the presence of this chromosomal abnormality leads to increased expression of BCR/ABL, which has also been reported in advanced disease stages [18] [19] [20] . However the relationships between BCR/ABL levels and presence of the second Ph chromosome has not been formally tested.
Whether the increased expression of BCR/ABL, per se, is sufficient to induce the phenotype of The t(7:11)(p15;p15) is an infrequent secondary abnormality in CML-BC, but the chimeric NUP98/HOXA9 protein appears to be relevant in disease progression. Mice inoculated with marrow cells expressing the NUP98/HOXA9 chimera developed a myeloproliforative disorder that progressed to AML after a latency of 4-9 months 142 . Co-expression of BCR/ABL and NUP98/HOXA9 caused a much more rapid disease process reminiscent of myeloid CML-BC 143, 144 . Of note, expression of HOXA9 was more abundant in 3 blast crisis samples compared to the corresponding chronic phase mononuclear fraction 144 , suggesting that activation of HOXA9 expression may be involved in disease progression also in CML-BC patients without the t(7;11)(p15;p15). Another interesting aspect of these studies relates to the mechanism(s) whereby NUP98/HOXA9 cooperates with BCR/ABL. NUP98/HOXA9 functions as a potent transcription factor 133 and induces a myeloproliferative disorder which appears to depend on increased proliferation and survival of myeloid progenitors 142 . The in vivo effects of NUP98/ HOXA9 are reminiscent of those of BCR/ABL but are markedly slower, thus allowing to distinguish a preleukemic and a frank leukemic stage 142 .
As elegantly proposed by Gilliland and collaborators 145 , AML appears to require at least two genetic events, one of which, exemplified by activating mutations of the FLT3 receptor, only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From endows cells with a proliferative and survival advantage, while the other, exemplified by formation of the PML-RAR chimera of the acute promyelocytic leukemia, provides a molecular mechanism for differentiation arrest. While this model is conceptually useful because it points to the existence of genetic mechanisms responsible for dysregulation of differentiation, often the differentiation arrest of leukemic cells (including CML-BC) is better explained by epigenetic mechanisms (i.e. suppression of C/EBP activity). In mouse models of CML-BC, the disease process induced by co-expression of BCR/ABL and AML-1/EVI-1 fits nicely with the requirement of two complementary mutations (one promoting proliferation, the other blocking differentiation), but that induced by BCR/ABL and NUP98/HOXA9 does not seem to depend, at least directly, on two clearly distinguishable functions. Arguably, the differentiation arrest of CML-BC cells expressing BCR/ABL and NUP98/HOXA9 is not due to a direct effect of NUP98/HOXA9 on differentiation regulatory pathways as increased proliferation and survival characterizes NUP98/HOXA9-expressing cells 142 . The cumulative activity of BCR/ABL and NUP98/HOXA9 is likely to cause the expansion of a stem-progenitor cell population no longer sensitive to differentiation-inducing stimuli.
Role of molecular abnormalities in CML disease progression
The most common gene mutations in CML-blast crisis involve the p53 gene (which is mutated in 25-30% of myeloid CML-blast crisis) and the INK4A/ARF exon 2 (which is homozygously deleted in approximately 50% of lymphoid CML-BC).
The pathogenic role of p53 loss of function in CML disease progression has been tested using two different strategies. We showed that mice injected with p53-deficient, BCR/ABLexpressing marrow cells developed a more aggressive disease process than those injected with wild-type p53, BCR/ABL-expressing marrow cells 146 . Compared to p53 wild-type cells, p53-deficient BCR/ABL-expressing marrow cells were homogeneously morphologically undifferentiated, more resistant to apoptosis induced by growth factor deprivation, and maintained high clonogenic potential in growth factor-deprived cultures 146 .
Blastic transformation of marrow cells was also obtained in a transgenic model in which mice expressing p210 BCR/ABL under the control of the Tec promoter were crossed with p53-heterozygous (p53+/-) mice 147 .
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The BCR/ABL+/-, p53+/-mice died of acute leukemia, which was preceded by a myeloproliferative disorder resembling human CML. Interestingly, the residual normal p53 allele of BCR/ABL-expressing blast cells was frequently lost, implying the existence of a BCR/ABL-dependent mechanism facilitating loss of the remaining p53 allele. In this transgenic model, all leukemias were clonal T-cell tumors, which is reminiscent of the spontaneously occurring T-cell lymphoma of p53-/-mice 148 . One interpretation of these findings is that BCR/ABL accelerates the tumorigenic conversion of cells prone to transformation by inactivation of one p53 allele.
Despite the absence of an ideal in vivo model testing the role of p53 loss of function in myeloid blast crisis, p53 loss can contribute to disease progression in several ways.
Compared to wild-type marrows, p53-/-cells showed a 3-4-fold increase in the frequency of multipotent progenitors (Lin-Sca-1 + , CD34 + ) and a greater number of hematopoietic stem cells capable of hematopoietic reconstitution in lethally irradiated mice 149 . Moreover, these cells were less susceptible to apoptotic stimuli 149 . Lineage commitment and differentiation of p53-/-progenitors was not affected, suggesting that loss of p53, per se, does not cause differentiation For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From suggesting a selective advantage for (pre)malignant lymphoid cells losing both ARF alleles 153, 154 .
Mice with a disruption of both alleles of p16INK4A and an intact p19ARF (p16INK4A -/-/p19ARF +/+ ) have only a moderately increased cancer susceptibility 155, 156 . interfering with its MDM2-dependent degradation 159 , homozygous deletion at the p16/ARF locus observed in lymphoid blast crisis might represent a functional equivalent of p53 mutation in myeloid blast crisis. However, ARF appears to have also p53-independent effects 160 , which could contribute to the phenotype of lymphoid blast crisis cells.
Loss of p16INK4A leads indirectly to abrogation/attenuation of the cell cycle regulatory effects of the p105 retinoblastoma protein (RB); however, the Rb gene itself is often inactivated in the accelerated or blast crisis phase of CML, especially that associated with a megakaryoblastic or lymphoblastic phenotype [161] [162] [163] . Rb is inactivated by mutation, deletion or loss of expression in approximately 18% of CML blast crisis cases.
A unifying mechanism for disease progression in CML
As discussed above, CML blast crisis is characterized by a number of seemingly incoherent chromosomal and molecular abnormalities. Yet, some generalizations can be homozygous deletion of the p16INK4A/ARF locus with secondary effects on the RB and p53 pathway) (Fig. 5) .
only. At the molecular level, CML blast crisis remains a heterogeneous disease and yet only few pathways are commonly affected. Of the many issues that need to be investigated for a better understanding of the pathogenic mechanisms in CML disease progression, some should attract considerable attention.
First, is BCR/ABL overexpression a common feature of CML-BC and is determined stochastically or by genetic/epigenetic mechanisms?
Recent evidence suggests that expression of BCR/ABL is more abundant in early than in late CML chronic phase progenitors 168 and that CML-BC undifferentiated and committed myeloid progenitors express higher BCR/ABL levels of the corresponding chronic phase The ultimate goal of BCR/ABL kinase inhibitor-based CML therapy is disease eradication and prevention of transition to blast crisis. Since it is unlikely that this will be achieved in each patient, understanding disease progression in the Gleevec-resistant group will be essential for the development of "rational" therapeutic strategies to be used in conjunction with BCR/ABL tyrosine kinase inhibitors. 
